Aptevo Therapeutics (APVO) Accumulated Expenses (2015 - 2026)

Aptevo Therapeutics has reported Accumulated Expenses for 12 years, with the latest figure at $803000.0 in Q1 2026.

• Quarterly Accumulated Expenses rose 70.13% year-over-year to $803000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $803000.0 (up 70.13% YoY) and the FY2025 annual result came in at $2.4 million, down 42.32% from the prior year.
• Accumulated Expenses retreated to $803000.0 in Q1 2026 per APVO's latest filing, from $2.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $4.9 million in Q2 2023 and troughed at $472000.0 in Q1 2025.
• A 5-year average of $2.7 million and a median of $2.9 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 81.7% in 2024, then jumped 225.45% in 2025.
• Over 5 years, Accumulated Expenses stood at $3.5 million in 2022, then grew by 13.86% to $4.0 million in 2023, then climbed by 5.35% to $4.2 million in 2024, then slumped by 42.32% to $2.4 million in 2025, then plunged by 66.83% to $803000.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $803000.0, $2.4 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.